Neurobiology of autism gene products: towards pathogenesis and drug targets
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
RationaleThe genetic heterogeneity of autism spectrum disorders (ASDs) is enormous, and the neurobiology of proteins encoded by genes associated with ASD is very diverse. Revealing the mechanisms on which different neurobiological pathways in ASD pathogenesis converge may lead to the identification of drug targets.ObjectiveThe main objective is firstly to outline the main molecular networks and neuronal mechanisms in which ASD gene products participate and secondly to answer the question how these converge. Finally, we aim to pinpoint drug targets within these mechanisms.MethodLiterature review of the neurobiological properties of ASD gene products with a special focus on the developmental consequences of genetic defects and the possibility to reverse these by genetic or pharmacological interventions.ResultsThe regulation of activity-dependent protein synthesis appears central in the pathogenesis of ASD. Through sequential consequences for axodendritic function, neuronal disabilities arise expressed as behavioral abnormalities and autistic symptoms in ASD patients. Several known ASD gene products have their effect on this central process by affecting protein synthesis intrinsically, e.g., through enhancing the mammalian target of rapamycin (mTOR) signal transduction pathway or through impairing synaptic function in general. These are interrelated processes and can be targeted by compounds from various directions: inhibition of protein synthesis through Lovastatin, mTOR inhibition using rapamycin, or mGluR-related modulation of synaptic activity.ConclusionsASD gene products may all feed into a central process of translational control that is important for adequate glutamatergic regulation of dendritic properties. This process can be modulated by available compounds but may also be targeted by yet unexplored routes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De novo mutations revealed by whole-exome sequencing are strongly associated with autism
Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willsey, A. J., Ercan-Sencicek, A. G., DiLullo, N. M., Parikshak, N. N., Stein, J. L., et al. (2012) · Nature · doi:10.1038/nature10945 · Cited by 2,084 · cited 1×
“The association of SHANK2 with ASD could be re-confirmed by following investigations identifying further SHANK2 mutations in more patients diagnosed with autism (Pinto et al. 2010; Leblond et al. 2012; Sanders et al. 2012; Chilian et al. 2013).”
BackgroundFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 6×
“It is not only engaged in receptor tyrosine kinase activation via PI3K/PTEN, Akt, and TSC1/TSC2, but also involved in downstream events triggered by mGluR1/5 activation via HOMER, PIKE, and Akt.”
BackgroundInfluentialFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013 · cited 2×
“The current number of candidate genes is staggering, with estimates ranging from several hundreds to a thousand, supported by ample literature (Pinto et al. 2010; Sanders et al. 2011; Cooper et al. 2011).”
BackgroundSelf-citationMutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism
Study, P. A. R. I. S., Jamain, S., Quach, H., Betancur, C., Råstam, M., Colineaux, C., Gillberg, I. C., Soderstrom, H., Giros, B., Leboyer, M., et al. (2003) · Nature Genetics · doi:10.1038/ng1136 · Cited by 1,851 · cited 15×
“NRXN1, NLGN3, and NLGN4X have come up as recurrent ASD genes in CNV studies as well as in mutational analyses.”
BackgroundSelf-citationNeuroligins and neurexins link synaptic function to cognitive disease
Südhof, T. C. (2008) · Nature · doi:10.1038/nature07456 · Cited by 1,849
Durand, C. M., Betancur, C., Boeckers, T. M., Bockmann, J., Chaste, P., Fauchereau, F., Nygren, G., Rastam, M., Gillberg, I. C., Anckarsäter, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1933 · Cited by 1,602 · cited 4×
“…mutation of Abelson’s Helper Intregration 1 (AHI1) (Alvarez Retuerto et al. 2008), Phelan-McDermid syndrome, involving SHANK3 as the critical gene (Durand et al. 2007; Phelan andMcDermid 2011), 3p deletion syndrome involving a microdeletion hitting three cell adhesion genes CNTN4, CHL1, and…”
BackgroundSelf-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 3×
“Particularly, targeting activity-dependent protein synthesis in animal models of FXS has proven successful and has pointed to the group I metabotropic receptors mGluR1 and mGluR5 as potential targets for ASD drug therapy (Bear et al. 2004; Dölen et al. 2007; Michalon et al. 2012).”
BackgroundShank3 mutant mice display autistic-like behaviours and striatal dysfunction
Peça, J., Feliciano, C., Ting, J. T., Wang, W., Wells, M. F., Venkatraman, T. N., Lascola, C. D., Fu, Z., & Feng, G. (2011) · Nature · doi:10.1038/nature09965 · Cited by 1,570 · cited 2×
“Taken together, this study introduced cortico-striatal dysfunction as one of the core deficits when Shank3 is lost in vivo (Peça et al. 2011).”
BackgroundBehavioural phenotyping assays for mouse models of autism
Silverman, J. L., Yang, M., Lord, C., & Crawley, J. N. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2851 · Cited by 1,462
A copy number variation morbidity map of developmental delay
Cooper, G. M., Coe, B. P., Girirajan, S., Rosenfeld, J. A., Vu, T. H., Baker, C., Williams, C., Stalker, H., Hamid, R., Hannig, V., et al. (2011) · Nature Genetics · doi:10.1038/ng.909 · Cited by 1,351
The Story of Rett Syndrome: From Clinic to Neurobiology
Chahrour, M., & Zoghbi, H. Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.10.001 · Cited by 1,265 · cited 2×
“In this review, however, we focus on neurobiological aspects of selected autism gene products, particularly those that are main subjects of the public–private research program EU-AIMS aiming for ASD drug development (Murphy and Spooren 2012).”
BackgroundSanders, S. J., Ercan-Sencicek, A. G., Hus, V., Luo, R., Murtha, M. T., Moreno-De-Luca, D., Chu, S. H., Moreau, M. P., Gupta, A. R., Thomson, S. A., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.002 · Cited by 1,263
Reversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230 · cited 3×
“In this review, however, we focus on neurobiological aspects of selected autism gene products, particularly those that are main subjects of the public–private research program EU-AIMS aiming for ASD drug development (Murphy and Spooren 2012).”
BackgroundPeñagarikano, O., Abrahams, B. S., Herman, E. I., Winden, K. D., Gdalyahu, A., Dong, H., Sonnenblick, L. I., Gruver, R., Almajano, J., Bragin, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.040 · Cited by 1,075 · cited 2×
“Cntnap2-null mice display a number of phenotypes in cortical neurons and autism-related behavioral consequences pointing to these early neurodevelopmental defects (Peñagarikano et al. 2011).”
BackgroundNaisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, C., Valtschanoff, J., Weinberg, R. J., Worley, P. F., & Sheng, M. (1999) · Neuron · doi:10.1016/s0896-6273(00)80809-0 · Cited by 1,009 · cited 1×
“They were originally identified as interaction partners of Cortactin and GKAP, respectively (Du et al. 1998; Boeckers et al. 1999; Naisbitt et al. 1999).”
BackgroundA Neuroligin-3 Mutation Implicated in Autism Increases Inhibitory Synaptic Transmission in Mice
Tabuchi, K., Blundell, J., Etherton, M. R., Hammer, R. E., Liu, X., Powell, C. M., & Südhof, T. C. (2007) · Science · doi:10.1126/science.1146221 · Cited by 997
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · cited 1×
“Particularly, targeting activity-dependent protein synthesis in animal models of FXS has proven successful and has pointed to the group I metabotropic receptors mGluR1 and mGluR5 as potential targets for ASD drug therapy (Bear et al. 2004; Dölen et al. 2007; Michalon et al. 2012).”
BackgroundPten Regulates Neuronal Arborization and Social Interaction in Mice
Kwon, C.-H., Luikart, B. W., Powell, C. M., Zhou, J., Matheny, S. A., Zhang, W., Li, Y., Baker, S. J., & Parada, L. F. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.023 · Cited by 970
Betancur, C. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.078 · Cited by 954
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882 · cited 9×
“A misbalance may occur when the loop is disturbed, for instance by a gene mutation that affects one component, like in TSC1/2 or FMRP, while the loop remains relatively in balance when both opposing components are lost simultaneously, like in a TSC1/2-FMRP double mutant (Auerbach et al. 2011).”
BackgroundInfluentialLinkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene
Alarcón, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., Sebat, J., Wigler, M., Martin, C. L., Ledbetter, D. H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.005 · Cited by 818
Groszer, M., Erickson, R., Scripture-Adams, D. D., Lesche, R., Trumpp, A., Zack, J. A., Kornblum, H. I., Liu, X., & Wu, H. (2001) · Science · doi:10.1126/science.1065518 · Cited by 798
Zoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797 · cited 1×
“Those syndromic forms with comorbid ASD that have a well-established genetic cause have been pivotal in delineating neurobiological processes involved (Zoghbi and Bear 2012).”
BackgroundButler, M. G., Dasouki, M. J., Zhou, X.-P., Talebizadeh, Z., Brown, M., Takahashi, T. N., Miles, J. H., Wang, C. H., Stratton, R., Pilarski, R., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024646 · Cited by 778 · cited 1×
“%) appeared to have a mutation in PTEN (Butler et al. 2005).”
BackgroundFMRP targets distinct mRNA sequence elements to regulate protein expression
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J. B., Nusbaum, J. D., Corcoran, D. L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., et al. (2012) · Nature · doi:10.1038/nature11737 · Cited by 701 · cited 7×
“It is not only engaged in receptor tyrosine kinase activation via PI3K/PTEN, Akt, and TSC1/TSC2, but also involved in downstream events triggered by mGluR1/5 activation via HOMER, PIKE, and Akt.”
BackgroundInfluentialGilman, S. R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M., & Vitkup, D. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.021 · Cited by 701 · cited 2×
“An example is a recent exome sequencing study that explains 1 % of sporadic ASDs by disrupting mutations in six genes, including PTEN (O’Roak et al. 2011).”
BackgroundAutistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function
Won, H., Lee, H.-R., Gee, H. Y., Mah, W., Kim, J.-I., Lee, J., Ha, S., Chung, C., Jung, E. S., Cho, Y. S., et al. (2012) · Nature · doi:10.1038/nature11208 · Cited by 695 · cited 3×
“…in vivo by the analysis of two different knockout mouse lines—the first one harboring a disruption of exon 7 (Schmeisser et al. 2012), the second one a disruption of exons 6 and 7 (Won et al. 2012) of Shank2, both targeting the PDZ domain and thus resulting in a lack of all known Shank2 isoforms.”
BackgroundPostnatal neurodevelopmental disorders: meeting at the synapse?
Zoghbi, H. Y. (2003) · Science · doi:10.1126/science.1089071 · Cited by 691
Contribution of SHANK3 Mutations to Autism Spectrum Disorder
Moessner, R., Marshall, C. R., Sutcliffe, J. S., Skaug, J., Pinto, D., Vincent, J., Zwaigenbaum, L., Fernandez, B., Roberts, W., Szatmari, P., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/522590 · Cited by 681 · cited 2×
“…deleterious SHANK3 mutations in patients with ASD and moreover in patients with other neurodevelopmental disorders such as intellectual disability, schizophrenia, and bipolar disorder (Moessner et al. 2007; Gauthier et al. 2009, 2010; Hamdan et al. 2011; Denayer et al. 2012; Boccuto et al. 2012).”
BackgroundActivity-dependent neuronal signalling and autism spectrum disorder
Ebert, D. H., & Greenberg, M. E. (2013) · Nature · doi:10.1038/nature11860 · Cited by 666 · cited 3×
“Activity-dependent local protein synthesis operates in dendrites on a selective population of mRNAs, regulates axodendritic functions, and assists neuronal circuits to integrate experience and environment (Ebert and Greenberg 2013).”
BackgroundAutistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2
Schmeisser, M. J., Ey, E., Wegener, S., Bockmann, J., Stempel, A. V., Kuebler, A., Janssen, A.-L., Udvardi, P. T., Shiban, E., Spilker, C., et al. (2012) · Nature · doi:10.1038/nature11015 · Cited by 638
Self-citationJacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“Clinical studies in FXS patients have been reported for Fenobam (Berry-Kravis et al. 2009) and AFQ056 (Jacquemont et al. 2011).”
BackgroundThe Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
The Autistic Neuron: Troubled Translation?
Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598 · cited 2×
“2) (Bear et al. 2008; Napoli et al. 2008; Kelleher and Bear 2008; Wang et al. 2009; Auerbach et al. 2011; Osterweil et al. 2013).”
BackgroundPartial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 1×
“…factors such as insulin-like growth factor I (Igf1) have been successfully used to significantly ameliorate and/or reverse synaptic and behavioral phenotypes in models of Rett Syndrome and Phelan McDermid Syndrome, respectively (Tropea et al. 2009; Bozdagi et al. 2013; Shcheglovitov et al. 2013).”
MethodBozdagi, O., Sakurai, T., Papapetrou, D., Wang, X., Dickstein, D. L., Takahashi, N., Kajiwara, Y., Yang, M., Katz, A. M., Scattoni, M. L., et al. (2010) · Molecular Autism · doi:10.1186/2040-2392-1-15 · Cited by 584
The Shank family of scaffold proteins
Sheng, M., & Kim, E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.1851 · Cited by 578
Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation
Berkel, S., Marshall, C. R., Weiss, B., Howe, J., Roeth, R., Moog, U., Endris, V., Roberts, W., Szatmari, P., Pinto, D., et al. (2010) · Nature Genetics · doi:10.1038/ng.589 · Cited by 563
Jamain, S., Radyushkin, K., Hammerschmidt, K., Granon, S., Boretius, S., Varoqueaux, F., Ramanantsoa, N., Gallego, J., Ronnenberg, A., Winter, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711555105 · Cited by 556
Self-citationGenetic architecture in autism spectrum disorder
Devlin, B., & Scherer, S. W. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.03.002 · Cited by 545
Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3
Wang, X., McCoy, P. A., Rodriguiz, R. M., Pan, Y., Je, H. S., Roberts, A. C., Kim, C. J., Berrios, J., Colvin, J. S., Bousquet-Moore, D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr212 · Cited by 537
Autism-related deficits via dysregulated eIF4E-dependent translational control
Gkogkas, C. G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D. B., Vasuta, C., Yee, S., Truitt, M., Dallaire, P., et al. (2013) · Nature · doi:10.1038/nature11628 · Cited by 522 · cited 2×
“Knockout of 4EBP led to overexpression of Nlgns and increased the ratio of excitatory to inhibitory inputs (Gkogkas et al. 2012).”
BackgroundChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Modeling Autism by SHANK Gene Mutations in Mice
Jiang, Y.-H., & Ehlers, M. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.016 · Cited by 488
Disruption of the neurexin 1 gene is associated with schizophrenia
Rujescu, D., Ingason, A., Cichon, S., Pietiläinen, O. P. H., Barnes, M. R., Toulopoulou, T., Picchioni, M., Vassos, E., Ettinger, U., Bramon, E., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn351 · Cited by 471
SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients
Shcheglovitov, A., Shcheglovitova, O., Yazawa, M., Portmann, T., Shu, R., Sebastiano, V., Krawisz, A., Froehlich, W., Bernstein, J. A., Hallmayer, J. F., et al. (2013) · Nature · doi:10.1038/nature12618 · Cited by 470 · cited 2×
“These findings were partially confirmed by Shcheglovitov et al. (2013), who demonstrated that a reduced level of SHANK3 in iPS cells of Phelan-McDermid Syndrome patients caused defects in excitatory synaptic transmission (Shcheglovitov et al. 2013).”
MethodResultThe 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)
Phelan, K., & McDermid, H. E. (2011) · Molecular Syndromology · doi:10.1159/000334260 · Cited by 460
Neuroligin-1 Deletion Results in Impaired Spatial Memory and Increased Repetitive Behavior
Blundell, J., Blaiss, C. A., Etherton, M. R., Espinosa, F., Tabuchi, K., Walz, C., Bolliger, M. F., Südhof, T. C., & Powell, C. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4517-09.2010 · Cited by 450
Etherton, M. R., Blaiss, C. A., Powell, C. M., & Südhof, T. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910297106 · Cited by 447
Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441 · cited 1×
“Several studies have shown that the effects from disruption of one of these genes can be rescued by inhibiting mTOR, another player in the pathway (Pten (Kwon et al. 2003; Zhou et al. 2009); tuberous sclerosis complex (TSC) (Ehninger et al. 2008a)).”
BackgroundLeblond, C. S., Heinrich, J., Delorme, R., Proepper, C., Betancur, C., Huguet, G., Konyukh, M., Chaste, P., Ey, E., Rastam, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002521 · Cited by 429 · cited 6×
“The association of SHANK2 with ASD could be re-confirmed by following investigations identifying further SHANK2 mutations in more patients diagnosed with autism (Pinto et al. 2010; Leblond et al. 2012; Sanders et al. 2012; Chilian et al. 2013).”
BackgroundSelf-citationA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 3×
“The notion that mGluR5 is a target in ASD demonstrates that synaptic activity is a point of convergence and a link to dendritic translation control. mGluR5 inhibitors, like MPEP, Fenobam, and CTEP, have been tested in several models of ASD (Antar et al. 2004; Spooren et al. 2012; Pop et al. 2012).”
BackgroundOsterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 1×
“It has been shown that partial inhibition of the ERK1/2 pathway resulted in restoration of normal levels of protein synthesis in an Fmr1-null mouse (Osterweil et al. 2010).”
BackgroundComparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia
Kirov, G., Gumus, D., Chen, W., Norton, N., Georgieva, L., Sari, M., O'Donovan, M. C., Erdogan, F., Owen, M. J., Ropers, H.-H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm323 · Cited by 377
Gauthier, J., Champagne, N., Lafrenière, R. G., Xiong, L., Spiegelman, D., Brustein, E., Lapointe, M., Peng, H., Côté, M., Noreau, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906232107 · Cited by 369 · cited 1×
“…deleterious SHANK3 mutations in patients with ASD and moreover in patients with other neurodevelopmental disorders such as intellectual disability, schizophrenia, and bipolar disorder (Moessner et al. 2007; Gauthier et al. 2009, 2010; Hamdan et al. 2011; Denayer et al. 2012; Boccuto et al. 2012).”
BackgroundYang, M., Bozdagi, O., Scattoni, M. L., Wöhr, M., Roullet, F. I., Katz, A. M., Abrams, D. N., Kalikhman, D., Simon, H., Woldeyohannes, L., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6107-11.2012 · Cited by 369
PTEN hamartoma tumor syndrome: an overview
Hobert, J. A., & Eng, C. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ac9aea · Cited by 366 · cited 1×
“They are collectively referred to as PHTS (Orloff and Eng 2008; Blumenthal and Dennis 2008; Hobert and Eng 2009).”
BackgroundHung, A. Y., Futai, K., Sala, C., Valtschanoff, J. G., Ryu, J., Woodworth, M. A., Kidd, F. L., Sung, C. C., Miyakawa, T., Bear, M. F., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3032-07.2008 · Cited by 350 · cited 1×
“In contrast, they show enhanced acquisition of spatial memory in the radial maze task but with impaired long-term retention of this memory after the training period has finished (Hung et al. 2008).”
BackgroundHamdan, F. F., Gauthier, J., Araki, Y., Lin, D.-T., Yoshizawa, Y., Higashi, K., Park, A.-R., Spiegelman, D., Dobrzeniecka, S., Piton, A., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.02.001 · Cited by 349 · cited 1×
“…deleterious SHANK3 mutations in patients with ASD and moreover in patients with other neurodevelopmental disorders such as intellectual disability, schizophrenia, and bipolar disorder (Moessner et al. 2007; Gauthier et al. 2009, 2010; Hamdan et al. 2011; Denayer et al. 2012; Boccuto et al. 2012).”
BackgroundBoeckers, T. M., Bockmann, J., Kreutz, M. R., & Gundelfinger, E. D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00931.x · Cited by 349
Self-citationSynapse Pathology in Psychiatric and Neurologic Disease
van Spronsen, M., & Hoogenraad, C. C. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0104-8 · Cited by 345 · cited 1×
“The cooperativity between GABAergic and glutamatergic terminals in de-regulation of dendritic spine morphology allows for diverse therapeutic strategies (van Spronsen and Hoogenraad 2010; Spooren et al. 2012).”
BackgroundChemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
A randomised controlled trial of bumetanide in the treatment of autism in children
Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., Hadjikhani, N., & Ben-Ari, Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.124 · Cited by 322
SHANK1 Deletions in Males with Autism Spectrum Disorder
Sato, D., Lionel, A. C., Leblond, C. S., Prasad, A., Pinto, D., Walker, S., O'Connor, I., Russell, C., Drmic, I. E., Hamdan, F. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.03.017 · Cited by 318 · cited 1×
“No equivalent SHANK1mutations were found in >15,000 controls (Sato et al. 2012).”
BackgroundSelf-citationBhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E. (2012) · Neuron · doi:10.1016/j.neuron.2012.07.022 · Cited by 316
Durand, C. M., Perroy, J., Loll, F., Perrais, D., Fagni, L., Bourgeron, T., Montcouquiol, M., & Sans, N. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.57 · Cited by 316 · cited 1×
“A second study by Durand et al. (2012) extended these initial findings in primary cultures and additionally included a de novo missense variation (Q321R) into the analysis primarily identified by Moessner et al. (2007) (Moessner et al. 2007; Durand et al. 2012).”
BackgroundSelf-citationThe conundrums of understanding genetic risks for autism spectrum disorders
State, M. W., & Levitt, P. (2011) · Nature Neuroscience · doi:10.1038/nn.2924 · Cited by 306
Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism
Baudouin, S. J., Gaudias, J., Gerharz, S., Hatstatt, L., Zhou, K., Punnakkal, P., Tanaka, K. F., Spooren, W., Hen, R., De Zeeuw, C. I., et al. (2012) · Science · doi:10.1126/science.1224159 · Cited by 293
Self-citationMinimal aberrant behavioral phenotypes of neuroligin‐3 R451C knockin mice
Chadman, K. K., Gong, S., Scattoni, M. L., Boltuck, S. E., Gandhy, S. U., Heintz, N., & Crawley, J. N. (2008) · Autism Research · doi:10.1002/aur.22 · Cited by 292 · cited 1×
“An example is a recent exome sequencing study that explains 1 % of sporadic ASDs by disrupting mutations in six genes, including PTEN (O’Roak et al. 2011).”
BackgroundAn Architectural Framework That May Lie at the Core of the Postsynaptic Density
Baron, M. K., Boeckers, T. M., Vaida, B., Faham, S., Gingery, M., Sawaya, M. R., Salyer, D., Gundelfinger, E. D., & Bowie, J. U. (2006) · Science · doi:10.1126/science.1118995 · Cited by 292 · cited 11×
“The discovery of apparent reduced penetrance of ASD in females bearing inherited autosomal SHANK1 deletions provides a possible contributory model for the male gender bias in autism.”
BackgroundSelf-citationAutism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling
Földy, C., Malenka, R. C., & Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.036 · Cited by 287 · cited 4×
“Even more strikingly, a recent study indicated that the NLGN3 R451C mutation may differentially affect two different types of presynapses onto the same postsynaptic neuron (Földy et al. 2013).”
BackgroundInfluentialBoeckers, T. M., Kreutz, M. R., Winter, C., Zuschratter, W., Smalla, K.-H., Sanmarti-Vila, L., Wex, H., Langnaese, K., Bockmann, J., Garner, C. C., et al. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-15-06506.1999 · Cited by 257 · cited 1×
“They were originally identified as interaction partners of Cortactin and GKAP, respectively (Du et al. 1998; Boeckers et al. 1999; Naisbitt et al. 1999).”
BackgroundSelf-citationDu, Y., Weed, S. A., Xiong, W.-C., Marshall, T. D., & Parsons, J. T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5838 · Cited by 254
Disorder-associated mutations lead to functional inactivation of neuroligins
Chih, B., Afridi, S. K., Clark, L., & Scheiffele, P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh158 · Cited by 242 · cited 2×
“…mutations, leading to retention of NLGN4 in the endoplasmic reticulum (Zhang et al. 2009) and preventing NLGN4-induced synapse formation in culture (Chih et al. 2004), although in one case a potential increase in NLGN4X transcription was also associated with an autism-like phenotype (Daoud et al.…”
BackgroundSelf-citationTargeting the endocannabinoid system in the treatment of fragile X syndrome
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., de la Torre, R., Dierssen, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3127 · Cited by 241
Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders
Boccuto, L., Lauri, M., Sarasua, S. M., Skinner, C. D., Buccella, D., Dwivedi, A., Orteschi, D., Collins, J. S., Zollino, M., Visconti, P., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.175 · Cited by 240
Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies
Grabrucker, A. M., Schmeisser, M. J., Schoen, M., & Boeckers, T. M. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.07.003 · Cited by 233 · cited 3×
“In general, SHANK proteins induce the formation of spines and excitatory synapses, while recent in vitro and in vivo studies implicate that each family member has its distinct function during these processes (Sheng and Kim 2000; Boeckers et al. 2002; Grabrucker et al. 2011b; Verpelli et al. 2012).”
BackgroundSelf-citationOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 3×
“2) (Bear et al. 2008; Napoli et al. 2008; Kelleher and Bear 2008; Wang et al. 2009; Auerbach et al. 2011; Osterweil et al. 2013).”
BackgroundAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229 · cited 1×
“Besides the genetic basis for ASD, it is argued that the role of epigenetic regulation and the effect of environmental factors, such as intrauterine drug exposure and perinatal infection, should not be excluded in the search for ASD causes (Chaste and Leboyer 2012; Grabrucker 2012; Millan 2013).”
BackgroundConcerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation
Grabrucker, A. M., Knight, M. J., Proepper, C., Bockmann, J., Joubert, M., Rowan, M., Nienhaus, G. U., Garner, C. C., Bowie, J. U., Kreutz, M. R., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.336 · Cited by 228
Self-citationWöhr, M., Roullet, F. I., Hung, A. Y., Sheng, M., & Crawley, J. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020631 · Cited by 220 · cited 1×
“However, Wöhr et al. (2011) showed reduced levels of ultrasonic vocalizations and scent-marking behavior in Shank1 knockouts, indicating a failure to learn from a social experience (Wöhr et al. 2011).”
BackgroundProgress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
Self-citationSociability and motor functions in Shank1 mutant mice
Silverman, J. L., Turner, S. M., Barkan, C. L., Tolu, S. S., Saxena, R., Hung, A. Y., Sheng, M., & Crawley, J. N. (2011) · Brain Research · doi:10.1016/j.brainres.2010.09.026 · Cited by 218
Fraser, M. M., Bayazitov, I. T., Zakharenko, S. S., & Baker, S. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.10.048 · Cited by 202 · cited 2×
“Anatomical abnormalities, mostly resulting in lamination defects, were found in studies in which Pten was ablated in early developmental stages (Backman et al. 2001; Kwon et al. 2001; Groszer et al. 2001; Fraser et al. 2004, 2008; Yue et al. 2005).”
BackgroundA role for primary cilia in glutamatergic synaptic integration of adult-born neurons
Kumamoto, N., Gu, Y., Wang, J., Janoschka, S., Takemaru, K.-I., Levine, J., & Ge, S. (2012) · Nature Neuroscience · doi:10.1038/nn.3042 · Cited by 196 · cited 2×
“It has been observed that cilia assemble precisely at the stage when newborn neurons approach their final destination, extend dendrites, and form synapses (Kumamoto et al. 2012).”
BackgroundReversing Neurodevelopmental Disorders in Adults
Ehninger, D., Li, W., Fox, K., Stryker, M. P., & Silva, A. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.12.007 · Cited by 196
Connecting Genes to Brain in the Autism Spectrum Disorders
Abrahams, B. S., & Geschwind, D. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.47 · Cited by 193 · cited 1×
“These genes have been considered prototypical for research into the molecular and cellular mechanisms of ASDs (Abrahams and Geschwind 2010).”
BackgroundPTEN signaling in autism spectrum disorders
Zhou, J., & Parada, L. F. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.05.004 · Cited by 188
Cilia in the nervous system: linking cilia function and neurodevelopmental disorders
Lee, J. E., & Gleeson, J. G. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283444d05 · Cited by 185 · cited 1×
“Primary cilia of the brain have been implicated in brain development and serve as signaling centers linked to the cell cycle and migration (Lee and Gleeson 2011; Novarino et al. 2011).”
BackgroundAutistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist
Lintas, C., & Persico, A. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.060871 · Cited by 178
Bozdagi, O., Tavassoli, T., & Buxbaum, J. D. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-9 · Cited by 176
Genetic advances in autism: heterogeneity and convergence on shared pathways
Bill, B. R., & Geschwind, D. H. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.04.004 · Cited by 164
Berkel, S., Tang, W., Treviño, M., Vogt, M., Obenhaus, H. A., Gass, P., Scherer, S. W., Sprengel, R., Schratt, G., & Rappold, G. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr470 · Cited by 162 · cited 2×
“In line with these findings, in vivo overexpression of R462X in mouse hippocampus and cortex leads to a reduction of mEPSC amplitude, densely packed filopodia instead of mature spines, and cognitive abnormalities (Berkel et al. 2012).”
BackgroundCampbell, D. B., Li, C., Sutcliffe, J. S., Persico, A. M., & Levitt, P. (2008) · Autism Research · doi:10.1002/aur.27 · Cited by 154
Lemonnier, E., & Ben‐Ari, Y. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2010.01933.x · Cited by 153 · cited 1×
“The hypothesis that the developmental GABA shift may provide a target for therapy was initially tested by treating five autistic children with the NKCC1 antagonist Bumetanide (Lemonnier and Ben-Ari 2010).”
BackgroundDeregulation of EIF4E: a novel mechanism for autism
Neves-Pereira, M., Müller, B., Massie, D., Williams, J. H. G., O’Brien, P. C. M., Hughes, A., Shen, S.-B., Clair, D. S., & Miedzybrodzka, Z. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066852 · Cited by 142
Kas, M. J., Glennon, J. C., Buitelaar, J., Ey, E., Biemans, B., Crawley, J., Ring, R. H., Lajonchere, C., Esclassan, F., Talpos, J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3268-5 · Cited by 132
Self-citationEhninger, D., De Vries, P. J., & Silva, A. J. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01208.x · Cited by 120 · cited 1×
“These models concerned PTEN−/−, Tsc1−/−, Tsc1+/− and Tsc2+/−mice and treatments with the mTOR inhibitors rapamycin, RAD001, or CCI-779 (Ehninger et al. 2009; Ehninger and Silva 2011).”
BackgroundSpooren, W., Lindemann, L., Ghosh, A., & Santarelli, L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.004 · Cited by 119 · cited 6×
“Convergence of molecular processes in which ASD genes participate may be exploited to design strategies that can be applied to patients with heterogeneous causes (Spooren et al. 2012; Ebert and Greenberg 2013).”
BackgroundMethodInfluentialDenayer, A., Van Esch, H., de Ravel, T., Frijns, J.-P., Van Buggenhout, G., Vogels, A., Devriendt, K., Geutjens, J., Thiry, P., & Swillen, A. (2012) · Molecular Syndromology · doi:10.1159/000339119 · Cited by 99
Deletion of α‐neurexins does not cause a major impairment of axonal pathfinding or synapse formation
Dudanova, I., Tabuchi, K., Rohlmann, A., Südhof, T. C., & Missler, M. (2007) · Journal of Comparative Neurology · doi:10.1002/cne.21305 · Cited by 98
Association of common variants in the Joubert syndrome gene (AHI1) with autism
Alvarez Retuerto, A. I., Cantor, R. M., Gleeson, J. G., Ustaszewska, A., Schackwitz, W. S., Pennacchio, L. A., & Geschwind, D. H. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn291 · Cited by 96 · cited 3×
“Mutations in AHI1 are a cause of JBTS and are associated in sporadic ASD (Alvarez Retuerto et al. 2008).”
BackgroundFragile X: translation in action
Bear, M. F., Dölen, G., Osterweil, E., & Nagarajan, N. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301610 · Cited by 94 · cited 1×
“2) (Bear et al. 2008; Napoli et al. 2008; Kelleher and Bear 2008; Wang et al. 2009; Auerbach et al. 2011; Osterweil et al. 2013).”
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant
Pop, A. S., Levenga, J., de Esch, C. E. F., Buijsen, R. A. M., Nieuwenhuizen, I. M., Li, T., Isaacs, A., Gasparini, F., Oostra, B. A., & Willemsen, R. (2014) · Psychopharmacology · doi:10.1007/s00213-012-2947-y · Cited by 93 · cited 1×
“The protein was originally discovered as an interacting protein of CNTN2 (a.k.a. TAG-1), in analogy with the protein interaction of CNTN1 (F3/contactin) and CNTNAP1 (a.k.a. Caspr) (Poliak et al. 1999).”
BackgroundScaffold Proteins at the Postsynaptic Density
Verpelli, C., Schmeisser, M. J., Sala, C., & Boeckers, T. M. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_2 · Cited by 92 · cited 3×
“In general, SHANK proteins induce the formation of spines and excitatory synapses, while recent in vitro and in vivo studies implicate that each family member has its distinct function during these processes (Sheng and Kim 2000; Boeckers et al. 2002; Grabrucker et al. 2011b; Verpelli et al. 2012).”
BackgroundSelf-citationChilian, B., Abdollahpour, H., Bierhals, T., Haltrich, I., Fekete, G., Nagel, I., Rosenberger, G., & Kutsche, K. (2013) · Clinical Genetics · doi:10.1111/cge.12105 · Cited by 85
Cited by
Medial prefrontal cortex in neurological diseases
Xu, P., Chen, A., Li, Y., Xing, X., & Lu, H. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00006.2019 · Cited by 341
Cell adhesion and matricellular support by astrocytes of the tripartite synapse
Hillen, A. E. J., Burbach, J. P. H., & Hol, E. M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.02.002 · Cited by 108
Self-citationFirst glimpses of the neurobiology of autism spectrum disorder
Sanders, S. J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.10.002 · Cited by 84
Hammer, M., Krueger-Burg, D., Tuffy, L. P., Cooper, B. H., Taschenberger, H., Goswami, S. P., Ehrenreich, H., Jonas, P., Varoqueaux, F., Rhee, J.-S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.011 · Cited by 66
“More than 50 mutations in NLGN4 have been identified in individuals with ASD (Chanda et al., 2015; Kleijer et al., 2014; S€udhof, 2008), most of which lead to a loss of function (Zhang et al., 2009).”
BackgroundSelf-citationCellot, G., & Cherubini, E. (2014) · Physiological Reports · doi:10.14814/phy2.12077 · Cited by 38
“…functional role of this adhesion molecule is still poorly understood, the R451C mutation leads to almost 90% retention of the protein in the endoplasmatic reticulum (Tabuchi et al. 2007), a condition that reduces the binding activity of the remaining molecules to b-neurexin 1 (Kleijer et al. 2014).”
Background
Metadata
- Authors
- Kleijer, K. T. E., Schmeisser, M. J., Krueger, D. D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H.
- Venue
- Psychopharmacology
- Published
- 2014-01-14
- Volume
- 231
- Issue
- 6
- Pages
- 1037-1062
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2155646587
- Cited by
- 75
- References
- 106
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.